# PLUS THERAPEUTICS, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/PLUS THERAPEUTICS, Inc). ## Overview Cerenome, Inc. is a U.S.-based CNS oncology company developing precision diagnostics and targeted radiotherapeutics for central nervous system cancers. Its platform combines the CNSide laboratory-developed diagnostic, rhenium (186Re) obisbemeda, 188RNL-BAM, proprietary data, and related manufacturing capabilities through subsidiaries and external partners. ## Products & services • CNSide® cerebrospinal-fluid diagnostic platform • Rhenium (186Re) obisbemeda radiotherapeutic • 188RNL-BAM solid-tumor radiotherapeutic candidate • CNS cancer clinical development programs • Proprietary microfluidic chips and diagnostic reagents - **Targeted CNS radiotherapeutics** (70%) — Radiopharmaceutical candidates designed for localized treatment of CNS cancers. - **CNS diagnostics** (10%) — CNSide® tests intended to identify tumor cells in cerebrospinal fluid. - **Solid-tumor radiotherapeutics** (15%) — 188RNL-BAM is being developed for liver and other solid-organ cancers. - **Manufacturing and platform capabilities** (5%) — Proprietary production workflows, microfluidic chips, reagents, and analytical capabilities support development programs. - CNSide® laboratory-developed diagnostic platform - Rhenium (186Re) obisbemeda radiotherapeutic candidate - 188RNL-BAM radiotherapeutic candidate for solid tumors - CNS cancer clinical development programs - Proprietary microfluidic chips and diagnostic reagents ## Customers Cerenome’s commercial and development customers include hospitals, cancer centers, neuro-oncology practices, clinical laboratories, and research institutions that may use CNSide or participate in clinical programs. Future radiotherapeutic customers are expected to include healthcare providers and treatment centers seeking localized options for glioblastoma, leptomeningeal metastases, pediatric brain cancers, and other solid tumors. Payers and distribution or manufacturing partners also influence adoption through reimbursement, supply, and commercialization requirements. - **Hospitals and cancer centers** (primary) — Potential users of CNSide and localized radiotherapeutic procedures for complex CNS cancers. - **Neuro-oncology practices** (primary) — Use diagnostic information and targeted treatment options in CNS cancer management. - **Clinical laboratories** (secondary) — Perform or support CNSide testing and related sample-processing workflows. - **Academic and clinical research institutions** (secondary) — Participate in trials and generate clinical evidence for product candidates. - **Pharmaceutical and manufacturing partners** (secondary) — Provide development, manufacturing, supply, or commercialization capabilities. - Hospitals and cancer centers use CNS diagnostics and radiotherapeutics - Neuro-oncology practices seek tools for CNS tumor assessment - Clinical laboratories may perform or support CNSide testing - Academic sites and investigators conduct sponsored clinical studies - Payers affect future access through coverage and reimbursement ## Geography Cerenome is headquartered and principally operates in the United States, with operations and facility expansion centered in Houston, Texas. Its clinical, regulatory, manufacturing, and commercial activities are U.S.-focused in the available reports, while future product candidates may require approvals and commercialization capabilities in additional jurisdictions. No country-level revenue percentages are disclosed in the provided excerpts. - Houston, Texas is the company’s principal operating location - Levit Green facilities support manufacturing and laboratory operations - U.S. hospitals and cancer centers are key development customers - U.S. FDA and state rules shape commercialization requirements - International expansion would require additional regulatory approvals ## Strategy Cerenome is building an integrated CNS oncology model that links precision diagnostics, targeted radiotherapeutics, and proprietary clinical data. Near-term priorities include commercializing CNSide, advancing rhenium (186Re) obisbemeda and 188RNL-BAM through clinical development, and expanding standardized production capacity. The company also uses contract research and manufacturing partners to extend capabilities while building internal analytical, ERP, and operational infrastructure. - **CNSide commercial rollout** (short-term) — Diagnostic revenue can establish a commercial entry point before therapeutic approvals. - **Advance targeted radiotherapeutics** (medium-term) — Clinical validation and regulatory progress are required to convert candidates into products. - **Build scalable operating infrastructure** (medium-term) — Standardized manufacturing and planning support higher clinical and commercial volumes. - **Integrate the CNS oncology platform** (long-term) — Combining diagnostics and therapeutics may improve disease characterization and treatment positioning. - Commercialize CNSide as an initial diagnostic revenue platform - Advance obisbemeda for glioblastoma and other CNS cancers - Develop 188RNL-BAM for liver and solid-organ tumors - Integrate diagnostics, therapeutics, and proprietary CNS data - Scale production and standardize operations at Levit Green - Use CROs and CMOs to expand development capabilities ## Risks Cerenome remains dependent on successful clinical development, regulatory approval, reimbursement, and commercialization of investigational products. Its development model also relies heavily on CROs, hospitals, clinical investigators, and CMOs, creating execution, supply, quality, and data-integrity exposure. Continuing losses and operating cash use increase financing and going-concern risk while competition may reduce future market access or pricing. - **Clinical development failure** [critical] — Negative efficacy, safety, or manufacturing data could end programs before approval. - **Regulatory approval failure** [critical] — Radiopharmaceuticals and diagnostics face extensive, costly, and unpredictable requirements. - **Third-party manufacturing dependence** [high] — CMO capacity, compliance, quality, or supply interruptions could delay trials or launch. - **Third-party clinical execution** [high] — CRO, hospital, or investigator failures could delay trials or compromise data integrity. - **Reimbursement and market adoption** [high] — Inadequate coverage, pricing, or treatment convenience could restrict demand. - **Financing and going-concern risk** [critical] — Operating cash use and continuing losses may require additional capital before products generate material revenue. - **Competitive displacement** [high] — Other biotechnology, pharmaceutical, device, and diagnostic companies may deliver safer or more effective alternatives. - Clinical trial failures could prevent product commercialization - FDA approval processes are costly, lengthy, and unpredictable - CMO dependence creates supply, quality, and scale-up risk - CRO and hospital failures could impair trial data integrity - Insufficient payer coverage could limit future adoption - Persistent losses may require additional external financing ## Accounting The company’s U.S. GAAP reporting depends on estimates for grants and awards, indefinite-lived intangible assets, share-based compensation, and warrant fair values. CNSide commercial billing introduces revenue-recognition considerations as diagnostic services and related obligations are delivered, while early-stage development costs and limited revenue can create significant period-to-period volatility. Going-concern disclosures, impairment assessments, and fair-value changes are particularly important given operating losses, financing activity, and development-stage assets. - **Diagnostic revenue recognition** — Timing and classification of emerging diagnostic revenue - **Grants and awards** — Potential changes to operating results and balance-sheet values - **Indefinite-lived intangible assets** — Non-cash impairment expense - **Share-based compensation** — Expense recognition and dilution analysis - **Warrant fair value** — Non-cash gains or losses and liability balances - **Going-concern assessment** — Financial statement disclosure and investor risk assessment - CNSide revenue timing depends on delivery of diagnostic services - Grant and award estimates affect assets, liabilities, and expenses - Intangible impairment testing may affect reported asset values - Share-based compensation affects operating expense and equity - Warrant fair values can create non-cash earnings volatility - Going-concern uncertainty affects financial statement disclosures --- *Last updated: 2026-09-24T10:46:56.212124+00:00*